Pyrilutamide

Pyrilutamide
Clinical data
Other namesKX-826; KX826
Routes of
administration		Topical
Drug classNonsteroidal antiandrogen; Androgen receptor antagonist
ATC code
  • None
Identifiers
  • 4-(3-(4-cyano-2-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC21H15F5N4O2S
Molar mass482.43 g·mol−1
3D model (JSmol)
  • CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=C(F)C(=C(C=C1)C#N)C(F)(F)F
  • InChI=1S/C21H15F5N4O2S/c1-20(2)18(32)29(14-7-4-10(9-27)15(16(14)23)21(24,25)26)19(33)30(20)11-5-6-12(13(22)8-11)17(31)28-3/h4-8H,1-3H3,(H,28,31)
  • Key:CGRMNGGGSWLDDC-UHFFFAOYSA-N

Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of androgenic alopecia (pattern hair loss) and acne. The drug is being developed by Suzhou Kintor Pharmaceuticals. As of February 2025, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne. The drug was also under development for the treatment of diabetic foot ulcers, but development for this indication was discontinued.

Pharmacology

Pharmacodynamics

Pyrilutamide is a selective and high-affinity silent antagonist of the androgen receptor (AR). It has an affinity (IC50Tooltip half-maximal inhibitory concentration) of 0.28 nM, relative to 3.1 nM in the case of bicalutamide.

See also

References

  1. 1 2 3 4 5 "Pyrilutamide - Suzhou Kintor Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R (January 2023). "What's New in Therapy for Male Androgenetic Alopecia?". American Journal of Clinical Dermatology. 24 (1): 15–24. doi:10.1007/s40257-022-00730-y. PMID 36169916.
  3. 1 2 CA patent 2829322, Tong Y, "Substituted Thioimidazolidinone Androgen Receptor Antagonists and Uses Thereof", published 2012-03-08, issued 2017-01-10, assigned to Suzhou Kintor Pharmaceuticals, Inc